3rd ADC Payload Summit

3rd ADC Payload Summit is organized by Hanson Wade and will be held from Nov 04 - 06, 2026 at Hotel Commonwealth Boston, Boston, Massachusetts, United States of America.

Description:
Diversifying ADC Payloads as Warheads for Overcoming Tumor Resistance, with Optimized Efficacy, Potency, & Differentiated Mechanisms of Action

As the ADC field becomes increasingly crowded with TOPO-1 and tubulin-based payloads, the pressure is on to identify differentiated mechanisms that can overcome resistance, improve therapeutic index, and deliver meaningful clinical advantage.

Recent billion-dollar transactions, including Novartis’ acquisition of Myricx Bio and its N-myristoyltransferase inhibitor payload platform, Gilead’s $5 billion acquisition of Tubulis to strengthen next-generation ADC technologies, and Johnson & Johnson’s acquisition of Firefly Bio’s degrader antibody conjugate platform, highlight the industry’s confidence in new approaches capable of expanding the therapeutic potential of ADCs.

The 3rd ADC Payload Summit is the only dedicated forum focused exclusively on payload innovation, bringing together 70+ leaders across payload chemistry, discovery biology, translational science, and R&D to tackle these challenges head-on.

Through deep-dive workshops, case studies, panel discussions, and the Brand-New Curated Matchmaking Roundtables, attendees will explore novel payload classes, dual-payload strategies, resistance mechanisms, translational modelling, and emerging approaches beyond traditional cytotoxicity.

Leave this meeting with the solutions to your key challenges around potency, safety, translation, and clinical success to deliver more effective therapies for patients.